StreetInsider.com News Articles

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 16:05:00 -0400

NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of July 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSU award will vest over three years, with 33 1/3% of the shares

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 16:05:00 -0400

The RSU award will vest over three years, with 33 1/3% of the shares

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 16:05:00 -0400

The RSU award will vest over three years, with 33 1/3% of the shares

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 16:05:00 -0400

The RSU award will vest over three years, with 33 1/3% of the shares

Karyopharm Therapeutics (KPTI) PT Lowered to $11 at Jefferies

Fri, 31 Jul 2026 10:31:22 -0400

Jefferies analyst Maury Raycroft lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $11.00 (from $14.00) while maintaining a Buy rating.

Karyopharm Therapeutics (KPTI) PT Lowered to $7 at Piper Sandler

Fri, 31 Jul 2026 08:35:37 -0400

Piper Sandler analyst Edward A. Tenthoff lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $7.00 (from $16.00) while maintaining a Overweight rating.

Form 8-K Karyopharm Therapeutics For: Jul 30

Fri, 31 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260731/26847292.html

Form 8-K Karyopharm Therapeutics For: Jul 30

Fri, 31 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260731/26847292.html

H.C. Wainwright Downgrades Karyopharm Therapeutics (KPTI) to Neutral

Fri, 31 Jul 2026 06:41:55 -0400

H.C. Wainwright analyst Robert Burns downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Buy to Neutral.

The analyst comments "XPORT-EC-042 primary endpoint miss weighs on Karyopharm's investment case. Yesterday, Karyopharm announced that the Phase 3 XPORT-EC-042 trial, which is evaluating selinexor versus placebo as maintenance therapy for patients with TP53wt advanced or recurrent endometrial cancer, failed to achieve statistical significance on its primary endpoint of PFS. The selinexor arm achieved a mPFS of 12.75 months compared with 7.43 months for the placebo arm, corresponding to a hazard ratio of 0.76 (95% CI: 0.51–1.12; one-sided p=0.0791). Relative to the topline and longer-term follow-up TP53wt

H.C. Wainwright Downgrades Karyopharm Therapeutics (KPTI) to Neutral

Fri, 31 Jul 2026 06:41:55 -0400

H.C. Wainwright analyst Robert Burns downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Buy to Neutral.

Baird Downgrades Karyopharm Therapeutics (KPTI) to Neutral

Fri, 31 Jul 2026 03:15:06 -0400

Baird analyst Colleen Kusy downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Outperform to Neutral with a price target of $3.00 (from $15.00).

The analyst comments: “Karyopharm announced topline data from the Phase 3 XPORT-EC-042 study evaluating selinexor (XPO1 inhibitor) as a maintenance therapy in TP53 wildtype (TP53wt) endometrial cancer (EC), which missed on the primary endpoint of PFS in TP53wt/ pMMR patients (mITT population; n=236). In this population, selinexor had mPFS of 12.75 months vs. 7.43 months in the placebo arm, equating to a hazard ratio of 0.76 (one-sided p-value=0.0791). We find these data surprising given the results from the previous Phase

Baird Downgrades Karyopharm Therapeutics (KPTI) to Neutral

Fri, 31 Jul 2026 03:15:06 -0400

Baird analyst Colleen Kusy downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Outperform to Neutral with a price target of $3.00 (from $15.00).

Form 4 Karyopharm Therapeutics For: Jul 28 Filed by: Poulton Stuart

Thu, 30 Jul 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260730/26844449.html

Form 4 Karyopharm Therapeutics For: Jul 28 Filed by: Poulton Stuart

Thu, 30 Jul 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260730/26844449.html

Karyopharm to file myelofibrosis drug application in August 2026

Thu, 30 Jul 2026 16:08:25 -0400

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) said it plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration in August 2026 seeking accelerated approval of selinexor in combination with ruxolitinib for the treatment of myelofibrosis.

The company said it will request Priority Review at the time of submission, which, if granted, would set a Prescription Drug User Fee Act target action date approximately six months after the FDA receives the application.

The planned submission follows FDA engagements in which the agency provided written feedback indicating that spleen volume reduction of 35% or more appears to qualify as

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –

– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –

– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –

– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Thu, 30 Jul 2026 16:06:00 -0400

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –
– Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results –
– Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit –
– If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the First Approved Combination Therapy for Patients with Myelofibrosis, Adding a Novel Class of